N. Sládek

发表

Inhibition by cyanamide of 4-hydroxycyclophosphamide/aldophosphamide oxidation to carboxyphosphamide.

B. Domeyer, N. Sládek, 1981, Biochemical pharmacology.

Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.

N. Sládek, G. J. Landkamer, 1985, Cancer research.

Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.

P. A. Maki, N. Sládek, 1991, Cancer research.

Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by chlorpropamide analogues.

V. R. Devaraj, L. Sreerama, N. Sládek, 1998, Biochemical pharmacology.

Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats.

N. Sládek, J. F. Powers, 1983, Cancer research.

Evidence for an aldehyde possessing alkylating activity as the primary metabolite of cyclophosphamide.

N. Sládek, 1973, Cancer research.

Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics

N. Sládek, G. Rekha, N. E. Sladek, 1997, Cancer Chemotherapy and Pharmacology.

Transient induction of increased aldehyde dehydrogenase 3A1 levels in cultured human breast (adeno)carcinoma cell lines via 5'-upstream xenobiotic, and electrophile, responsive elements is, respectively, estrogen receptor-dependent and -independent.

N. Sládek, 2003, Chemico-biological interactions.

Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies.

L. Sreerama, N. Sládek, L Sreerama, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Aldehyde Dehydrogenases: Measurement of Activities and Protein Levels

L. Sreerama, N. Sládek, 2005, Current protocols in toxicology.

Three different stable human breast adenocarcinoma sublines that overexpress ALDH3A1 and certain other enzymes, apparently as a consequence of constitutively upregulated gene transcription mediated by transactivated EpREs (electrophile responsive elements) present in the 5'-upstream regions of these

L. Sreerama, N. Sládek, 2001, Chemico-biological interactions.

Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol.

N. Sládek, G. Rekha, 1997, Advances in experimental medicine and biology.

Over-expression of glutathione S-transferases, DT-diaphorase and an apparently tumour-specific cytosolic class-3 aldehyde dehydrogenase by Warthin tumours and mucoepidermoid carcinomas of the human parotid gland.

L. Sreerama, N. Sládek, 1996, Archives of oral biology.

Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde.

Mi-Ock Lee, N. Sládek, M. O. Lee, 1992, Biochemical pharmacology.

Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.

L. Sreerama, N. Sládek, 1994, Cancer research.

Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli.

L. Sreerama, N. Sládek, M. Hedge, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells.

L. Sreerama, M. Schweder, N. Sládek, 1995, Leukemia & lymphoma.

Overexpression or polycyclic aromatic hydrocarbon-mediated induction of an apparently novel class 3 aldehyde dehydrogenase in human breast adenocarcinoma cells and its relationship to oxazaphosphorine-specific acquired resistance.

L. Sreerama, N. Sládek, 1993, Advances in experimental medicine and biology.

Human breast adenocarcinoma MCF-7/0 cells electroporated with cytosolic class 3 aldehyde dehydrogenases obtained from tumor cells and a normal tissue exhibit differential sensitivity to mafosfamide.

L. Sreerama, N. Sládek, 1995, Drug metabolism and disposition: the biological fate of chemicals.

Metabolism of oxazaphosphorines.

N. Sládek, 1988, Pharmacology & therapeutics.

Sensitivity of murine B- and T-lymphocytes to oxazaphosphorine and non-oxazaphosphorine nitrogen mustards.

N. Sládek, P. Smith, 1985, Biochemical pharmacology.

Identification of mouse liver aldehyde dehydrogenases that catalyze the oxidation of retinaldehyde to retinoic acid.

C. Manthey, N. Sládek, M. O. Lee, 1991, Biochemical pharmacology.

Therapeutic efficacy of cyclophosphamide as a function of its metabolism.

N. Sládek, 1972, Cancer research.

Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide.

F. Uckun, N. Sládek, M. Chandan-langlie, 1994, Leukemia & lymphoma.

Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.

N. Sládek, W. Krivit, D. Doeden, 1984, Cancer treatment reports.

PLasma half-life and urinary excretion of cyclophosphamide in children.

J. Priest, C. J. Mirocha, N. Sládek, 1980, Cancer treatment reports.

Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines.

C. Manthey, F. Kohn, N. Sládek, 1987, Cancer research.

Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s).

N. Sládek, 2002, Cancer treatment and research.

Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).

F. Kohn, N. Sládek, 1987, Biochemical pharmacology.

Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557).

F. Kohn, N. Sládek, G. J. Landkamer, 1987, Immunopharmacology and immunotoxicology.

Metabolism of cyclophosphamide by rat hepatic microsomes.

N. Sládek, 1971, Cancer research.

Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolism.

N. Sládek, 1972, Cancer research.

Sex-dependent differences in drug metabolism in the rat. IV. Effect of morphine administration.

N. Sládek, G. Mannering, M. Chaplin, 1974, Drug metabolism and disposition: the biological fate of chemicals.

Asymmetrical retinoic acid synthesis in the dorsoventral axis of the retina.

U. Dräger, Mi-Ock Lee, N. Sládek, 1992, Development.

Potentiation of antitumor drug action by centrophenoxine: specificity.

N. Sládek, 1977, The Journal of pharmacology and experimental therapeutics.

Potentiation of the cytotoxic action of melphalan and "activated" cyclophosphamide against cultured tumor cells by centrophenoxine.

N. Sládek, 1977, The Journal of pharmacology and experimental therapeutics.

Induction of drug metabolism. I. Differences in the mechanisms by which polycyclic hydrocarbons and phenobarbital produce their inductive effects on microsomal N-demethylating systems.

N. Sládek, G. Mannering, G. J. Mannering, 1969, Molecular pharmacology.

Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene treated rats.

N. Sládek, G. Mannering, G. J. Mannering, 1966, Biochemical and biophysical research communications.

Induction of Drug Metabolism: II. Qualitative Differences in the Microsomal N-Demethylating Systems Stimulated by Polycyclic Hydrocarbons and by Phenobarbital

N. Sládek, G. Mannering, G. J. Mannering, 1969 .

Xenobiotic oxidation catalyzed by aldehyde dehydrogenases.

P. A. Maki, C. Manthey, N. Sládek, 1989, Drug metabolism reviews.

Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo.

N. Sládek, 1973, Cancer research.

Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study

Lakshmaiah Sreerama, L. Sreerama, D. Kiang, 2002, Cancer Chemotherapy and Pharmacology.

A POSSIBLE ROLE OF THE ENDOPLASMIC RETICULUM IN THE REGULATION OF GENETIC EXPRESSION THE MEMBRON CONCEPT1

H. Pitot, J. Jost, R. Murray..., 1969 .

Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines.

N. Sládek, G. J. Landkamer, J. Low, 1985, Cancer research.

Constitutive and overexpressed human cytosolic class-3 aldehyde dehydrogenases in normal and neoplastic cells/secretions.

L. Sreerama, N. Sládek, G. Rekha, 1995, Advances in experimental medicine and biology.

Kinetics of cyclophosphamide biotransformation in vivo.

B. Domeyer, N. Sládek, 1980, Cancer research.

Ex vivo treatment of murine splenocyte-supplemented bone marrow inocula with mafosfamide prior to allogeneic transplantation in an attempt to prevent lethal graft-versus-host disease without compromising engraftment.

F. Kohn, N. Sládek, Norman E. Sladek, 1988, Immunopharmacology and immunotoxicology.

Half-life of oxazaphosphorines in biological fluids.

N. Sládek, J. F. Powers, G. Grage, 1984, Drug metabolism and disposition: the biological fate of chemicals.

Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification.

C. Manthey, N. Sládek, G. J. Landkamer, 1990, Cancer research.

Human aldehyde dehydrogenases: Potential pathological, pharmacological, and toxicological impact

N. Sládek, 2003, Journal of biochemical and molecular toxicology.

Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.

F. Kohn, N. Sládek, Fred R. Kohn, 1985, Biochemical pharmacology.

Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines.

L. Sreerama, N. Sládek, P. A. Dockham, 1997, Drug metabolism and disposition: the biological fate of chemicals.

NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide.

N. Sládek, H. Parekh, 1993, Biochemical pharmacology.

Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.

L. Sreerama, N. Sládek, 1993, Biochemical pharmacology.

Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.

N. Sládek, R. Borch, J. Low, 1983, Cancer research.

Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.

N. Sládek, R. Borch, J. Low, 1982, Cancer research.

Metabolism of 4-hydroxycyclophosphamide/aldophosphamide in vitro.

B. Domeyer, N. Sládek, 1980, Biochemical pharmacology.

Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide.

P. A. Maki, N. Sládek, Patricia A. Maki, 1993, Biochemical pharmacology.

FORMATION OF A NEW P-450 HEMOPROTEIN AFTER TREATMENT OF RATS WITH POLYCYCLIC HYDROCARBONS

N. Sládek, G. Mannering, D. Shoeman, 1969 .

Differential effects of Walker 256 carcinosarcoma cells growing subcutaneously, intramuscularly, or intraperitoneally on hepatic microsomal mixed-function oxygenase activity.

B. Domeyer, N. Sládek, R. Merriman, 1978, Drug metabolism and disposition: the biological fate of chemicals.

Yeast aldehyde dehydrogenase sensitivity to inhibition by chlorpropamide analogues as an indicator of human aldehyde dehydrogenase sensitivity to these agents.

V. R. Devaraj, L. Sreerama, N. Sládek, 1997, Advances in experimental medicine and biology.

The use of immortalized mouse L1210/OAP cells established in culture to study the major class 1 aldehyde dehydrogenase-catalyzed oxidation of aldehydes in intact cells.

N. Sládek, M. O. Lee, 1993, Advances in experimental medicine and biology.

Class 1 and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents.

L. Sreerama, N. Sládek, 1997, Advances in experimental medicine and biology.

Human and mouse hepatic aldehyde dehydrogenases important in the biotransformation of cyclophosphamide and the retinoids.

N. Sládek, M. O. Lee, P. A. Dockham, 1991, Advances in experimental medicine and biology.

Ultraviolet radiation decreases expression and induces aggregation of corneal ALDH3A1.

V. Vasiliou, J. Carpenter, Aglaia Pappa, 2003, Chemico-biological interactions.

Influence of pH on the cytotoxic activity of chlorambucil.

N. Sládek, G. Brophy, Gregory T. Brophy, 1983, Biochemical pharmacology.

Microdetermination of caffeine in blood by gas chromatography--mass spectrometry.

N. Sládek, M. W. Anders, R. Merriman, 1978, Journal of chromatography.

Interaction between duck hepatitis virus and DDT in ducks.

N. Sládek, M. Friend, D. Trainer, 1971, Research communications in chemical pathology and pharmacology.

Kinetics of Cyclophosphamide Biotransformation in

B. Domeyer, N. Sládek, 2006 .

Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity.

N. Sládek, R. Borch, J. F. Powers, 1982, Cancer treatment reports.

Phenolic antioxidant-induced overexpression of class-3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance.

L. Sreerama, N. Sládek, G. Rekha, 1995, Biochemical pharmacology.

Studies on the mechanism of template stability: cytoplasmic DNA-like RNA in hepatocellular carcinomas.

H. Pitot, N. Sládek, 1970, Cancer research.

Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines.

N. Sládek, 1999, Current pharmaceutical design.

Identification of the class-3 aldehyde dehydrogenases present in human MCF-7/0 breast adenocarcinoma cells and normal human breast tissue.

L. Sreerama, N. Sládek, 1994, Biochemical pharmacology.

Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants

L. Sreerama, N. Sládek, 2001, Cancer Chemotherapy and Pharmacology.

Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase.

L. Sreerama, N. Sládek, G. Rekha, 1994, Biochemical pharmacology.

Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases.

C. Manthey, N. Sládek, 1988, Biochemical Pharmacology.

Inhibition of ALDH3A1-catalyzed oxidation by chlorpropamide analogues.

N. Sládek, G. Rekha, M. Lee, 2001, Chemico-biological interactions.